Tegobuvir
- Generic Name
- Tegobuvir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H14F7N5
- CAS Number
- 1000787-75-6
- Unique Ingredient Identifier
- 5NOK5X389M
- Background
Tegobuvir has been investigated for the treatment of Hepatitis C, Chronic.
- Associated Conditions
- -
- Associated Therapies
- -
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-09-16
- Last Posted Date
- 2013-12-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 170
- Registration Number
- NCT01435226
- Locations
- 🇺🇸
Advanced Clinical Research Institute, LLC, Anaheim, California, United States
🇺🇸Lightsource Medical, Los Angeles, California, United States
🇺🇸Medical Associates Research Group, Inc., San Diego, California, United States
GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-05-13
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 141
- Registration Number
- NCT01353248
- Locations
- 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath